Barhemsys的批准涵盖了已使用一种不同类别的止吐药预防性治疗PONV的手术患者或没有接受止吐药预防性治疗PONV的手术患者，以及单独使用或与不同 ...

2020年02月28日讯 /生物谷BIOON/ --Acacia制药集团近日宣布，美国食品和药物管理局（FDA）已批准Barhemsys（amisulpride injection，氨磺必 ...

来自德国的研究人员针对术后24-48小时内发生的恶心呕吐(PONV)开展系统研究，通过整合患者、麻醉和手术相关风险因素，开发出预测敏感性达65-70%的简化风险评分量表(Apfel评分)，提出包含麻醉方案调整、药物与非药物干预的多模式防治策略，为临床PONV精准防控 ...

术后恶心呕吐（PONV）困扰患者并阻碍康复，术前风险评分缺乏生物标志物。研究人员开展血浆生长分化因子 - 15（GDF-15）与 PONV 关联研究，发现术前 GDF-15 浓度低或低维持轨迹者 PONV 风险高，GDF-15 或成有用生物标志物。 术后恶心呕吐（postoperative nausea and vomiting ...

术后恶心和呕吐(PONV)可以导致患者程度不等的不适，使患者无法口服药物、食物或液体，严重者可致伤口裂开、切口疝形成、误吸性肺炎、水电解质 ...

Acacia Pharma’s BARHEMSYS ® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV) Cambridge ...

The purpose of the analysis was to evaluate the plasma concentrations of a single dose of IV amisulpride 10 mg for rescue treatment of PONV. The PK data from a subset of patients in this Phase III ...

LONDON – It was third time lucky for Acacia Pharma Group plc, as the FDA finally gave approval to Barhemsys (amisulpride) as a rescue treatment for surgical patients suffering postoperative nausea and ...

The ASC developed such a policy and when it restudied the extended stays, they had decreased significantly because of the PONV standardization, says Ms. Desko. Below is a sample version of ASC Durango ...